Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the safety and tolerability of a ragweed allergy
immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years
of age and older with ragweed-induced rhinoconjunctivitis, with or without asthma.